Summary
192.61 11.92(6.60%)08/27/2024
Insulet Corporation (PODD)
Insulet Corporation (PODD)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 6.64 | 5.52 | 0.46 | 8.35 | 15.60 | 6.29 | 27.18 | 1,106.83 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 192.61 | |
| Open | 186.15 | |
| High | 196.48 | |
| Low | 183.31 | |
| Volume | 1,050,965 | |
| Change | 12.00 | |
| Change % | 6.64 | |
| Avg Volume (20 Days) | 654,456 | |
| Volume/Avg Volume (20 Days) Ratio | 1.61 | |
| 52 Week Range | 125.82 - 223.50 | |
| Price vs 52 Week High | -13.82% | |
| Price vs 52 Week Low | 53.08% | |
| Range | 3.47 | |
| Gap Up/Down | 0.99 | |
Fundamentals | ||
| Market Capitalization (Mln) | 13,503 | |
| EBIDTA | 338,800,000 | |
| PE Ratio | 49.8198 | |
| PEG Ratio | 3.1485 | |
| WallStreet Target Price | 234.90 | |
| Book Value | 11.3030 | |
| Earnings Per Share | 3.3300 | |
| EPS Estimate Current Quarter | 0.3900 | |
| EPS Estimate Next Quarter | 0.5600 | |
| EPS Estimate Current Year | 3.0200 | |
| EPS Estimate Next Year | 3.8200 | |
| Diluted EPS (TTM) | 3.3300 | |
| Revenues | ||
| Profit Marging | 0.1314 | |
| Operating Marging (TTM) | 0.1288 | |
| Return on asset (TTM) | 0.0674 | |
| Return on equity (TTM) | 0.3618 | |
| Revenue TTM | 1,780,700,032 | |
| Revenue per share TTM | 25.4950 | |
| Quarterly Revenue Growth (YOY) | 0.2330 | |
| Quarterly Earnings Growth (YOY) | 1.1470 | |
| Gross Profit (TTM) | 805,600,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 49.8198 | |
| Forward PE | 61.3497 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 16.7511 | |
| Revenue Enterprise Value | 7.6514 | |
| EBITDA Enterprise Value | 40.1271 | |
| Shares | ||
| Shares Outstanding | 70,039,504 | |
| Shares Float | 69,556,846 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.06 | |
| Insider (%) | 0.33 | |
| Institutions (%) | 104.23 | |
08/27 18:35 EST - investopedia.com
S&P 500 Gains and Losses Today: Medical Device Makers ResMed, Insulet Lead Index
Major U.S. equities indexes ticked higher ahead of a potentially consequential earnings report from semiconductor giant Nvidia (NVDA) as well as key inflation and economic data set for release later in the week.
S&P 500 Gains and Losses Today: Medical Device Makers ResMed, Insulet Lead Index
Major U.S. equities indexes ticked higher ahead of a potentially consequential earnings report from semiconductor giant Nvidia (NVDA) as well as key inflation and economic data set for release later in the week.
08/27 11:55 EST - zacks.com
Insulet's Omnipod 5 Wins FDA Approval for Type 2 Diabetes
PODD marks a major milestone with Omnipod 5 approval for the treatment of type 2 diabetes.
Insulet's Omnipod 5 Wins FDA Approval for Type 2 Diabetes
PODD marks a major milestone with Omnipod 5 approval for the treatment of type 2 diabetes.
08/27 11:32 EST - barrons.com
This Healthcare Stock Is the Best Performer in the S&P 500 Tuesday
Insulet got a key FDA approval for an insulin delivery system.
This Healthcare Stock Is the Best Performer in the S&P 500 Tuesday
Insulet got a key FDA approval for an insulin delivery system.
08/26 16:20 EST - businesswire.com
Omnipod® 5 Automated Insulin Delivery System is now FDA-cleared for People with Type 2 Diabetes
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its groundbreaking Omnipod 5 Automated Insulin Delivery System (Omnipod 5) is now indicated for use by people with type 2 diabetes (ages 18 years and older) in the U.S., making it the first and only AID system FDA-cleared for both type 1 and type 2 diabetes management. “Today's announcement represen.
Omnipod® 5 Automated Insulin Delivery System is now FDA-cleared for People with Type 2 Diabetes
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its groundbreaking Omnipod 5 Automated Insulin Delivery System (Omnipod 5) is now indicated for use by people with type 2 diabetes (ages 18 years and older) in the U.S., making it the first and only AID system FDA-cleared for both type 1 and type 2 diabetes management. “Today's announcement represen.
08/20 17:52 EST - investopedia.com
These Two Stocks Plunged After Eli Lilly Drug Study Showed Diabetes Promise
Shares of Insulet (PODD) and DexCom (DXCM), two companies that provide medical devices for patients managing diabetes, tumbled Tuesday after a study showed that a popular drug made by Eli Lilly (LLY) significantly lowers the risk of developing type 2 diabetes.
These Two Stocks Plunged After Eli Lilly Drug Study Showed Diabetes Promise
Shares of Insulet (PODD) and DexCom (DXCM), two companies that provide medical devices for patients managing diabetes, tumbled Tuesday after a study showed that a popular drug made by Eli Lilly (LLY) significantly lowers the risk of developing type 2 diabetes.
08/14 03:00 EST - businesswire.com
Insulet Celebrates Grand Opening of 400,000-square-foot Manufacturing Facility in Malaysia
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today hosted a grand opening celebration at its new manufacturing facility in Johor Bahru, Malaysia. “Insulet's remarkable growth is driven by our market-leading Omnipod 5, the first and only tubeless automated insulin delivery system in the U.S.,” said Jim Hollingshead, Insulet President and Chief Executive Office.
Insulet Celebrates Grand Opening of 400,000-square-foot Manufacturing Facility in Malaysia
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today hosted a grand opening celebration at its new manufacturing facility in Johor Bahru, Malaysia. “Insulet's remarkable growth is driven by our market-leading Omnipod 5, the first and only tubeless automated insulin delivery system in the U.S.,” said Jim Hollingshead, Insulet President and Chief Executive Office.
08/09 17:51 EST - investopedia.com
Insulin Pump Maker Insulet's Stock Slumps on User Growth Concerns
Shares of Insulet (PODD) suffered the heaviest losses of any S&P 500 stock on Friday, dropping 8.8% after the maker of insulin management devices suggested new user growth could be lower than previously expected in the second half of 2024, despite topping second-quarter sales estimates.
Insulin Pump Maker Insulet's Stock Slumps on User Growth Concerns
Shares of Insulet (PODD) suffered the heaviest losses of any S&P 500 stock on Friday, dropping 8.8% after the maker of insulin management devices suggested new user growth could be lower than previously expected in the second half of 2024, despite topping second-quarter sales estimates.
08/09 13:19 EST - barrons.com
Insulet Is the Worst Stock in S&P 500 Today, Despite Solid Earnings. Here's Why.
The automated insulin technology developer stock is on track for its largest percentage decline since February.
Insulet Is the Worst Stock in S&P 500 Today, Despite Solid Earnings. Here's Why.
The automated insulin technology developer stock is on track for its largest percentage decline since February.
08/09 10:48 EST - benzinga.com
Insulin Pump Maker Insulet's Growth Catalysts Set to Boost Revenue in 2025: Analyst
Insulin device maker Insulet Corporation PODD reported a second-quarter adjusted EPS of $0.55 on Thursday, missing the consensus estimate of $0.56. It reported an EPS of $0.38 a year ago.
Insulin Pump Maker Insulet's Growth Catalysts Set to Boost Revenue in 2025: Analyst
Insulin device maker Insulet Corporation PODD reported a second-quarter adjusted EPS of $0.55 on Thursday, missing the consensus estimate of $0.56. It reported an EPS of $0.38 a year ago.
08/09 10:25 EST - zacks.com
Insulet (PODD) Q2 Earnings Miss Estimates, '24 Sales View Raised
Insulet's (PODD) second-quarter performance benefits from the continued high demand for Omnipod 5.
Insulet (PODD) Q2 Earnings Miss Estimates, '24 Sales View Raised
Insulet's (PODD) second-quarter performance benefits from the continued high demand for Omnipod 5.
08/08 20:27 EST - seekingalpha.com
Insulet Corporation (PODD) Q2 2024 Earnings Call Transcript
Insulet Corporation (NASDAQ:PODD ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Deborah Gordon - Vice President, Investor Relations Jim Hollingshead - President & Chief Executive Officer Ana Maria Chadwick - Executive Vice President & Chief Financial Officer Conference Call Participants Robbie Marcus - JPMorgan Jeff Johnson - Baird Larry Biegelsen - Wells Fargo Margaret Kaczor - William Blair Travis Steed - Bank of America Michael Polark - Wolfe Research Matt Taylor - Jefferies Chris Pasquale - Nephron Mike Kratky - Leerink Partners Jayson Bedford - Raymond James Matthew O'Brien - Piper Sandler Steve Lichtman - Oppenheimer & Co. Joanne Wuensch - Citibank Operator Good afternoon, ladies and gentlemen, and welcome to the Insulet Corporation Second Quarter 2024 Earnings Call. At this time, all participants are in a listen-only mode.
Insulet Corporation (PODD) Q2 2024 Earnings Call Transcript
Insulet Corporation (NASDAQ:PODD ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Deborah Gordon - Vice President, Investor Relations Jim Hollingshead - President & Chief Executive Officer Ana Maria Chadwick - Executive Vice President & Chief Financial Officer Conference Call Participants Robbie Marcus - JPMorgan Jeff Johnson - Baird Larry Biegelsen - Wells Fargo Margaret Kaczor - William Blair Travis Steed - Bank of America Michael Polark - Wolfe Research Matt Taylor - Jefferies Chris Pasquale - Nephron Mike Kratky - Leerink Partners Jayson Bedford - Raymond James Matthew O'Brien - Piper Sandler Steve Lichtman - Oppenheimer & Co. Joanne Wuensch - Citibank Operator Good afternoon, ladies and gentlemen, and welcome to the Insulet Corporation Second Quarter 2024 Earnings Call. At this time, all participants are in a listen-only mode.
08/08 20:07 EST - reuters.com
Insulet inventory pressures cloud annual revenue forecast raise
Insulet Corp PODD.O on Thursday raised its annual revenue growth forecast but pressures over unutilised inventory clouded the upbeat outlook, sending shares of the insulin device maker down about 3.5% in extended trading.
Insulet inventory pressures cloud annual revenue forecast raise
Insulet Corp PODD.O on Thursday raised its annual revenue growth forecast but pressures over unutilised inventory clouded the upbeat outlook, sending shares of the insulin device maker down about 3.5% in extended trading.
08/08 18:31 EST - zacks.com
Insulet (PODD) Reports Q2 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Insulet (PODD) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Insulet (PODD) Reports Q2 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Insulet (PODD) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
08/08 18:20 EST - zacks.com
Insulet (PODD) Q2 Earnings Miss Estimates
Insulet (PODD) came out with quarterly earnings of $0.55 per share, missing the Zacks Consensus Estimate of $0.57 per share. This compares to earnings of $0.38 per share a year ago.
Insulet (PODD) Q2 Earnings Miss Estimates
Insulet (PODD) came out with quarterly earnings of $0.55 per share, missing the Zacks Consensus Estimate of $0.57 per share. This compares to earnings of $0.38 per share a year ago.
08/05 10:22 EST - zacks.com
Unlocking Q2 Potential of Insulet (PODD): Exploring Wall Street Estimates for Key Metrics
Beyond analysts' top -and-bottom-line estimates for Insulet (PODD), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2024.
Unlocking Q2 Potential of Insulet (PODD): Exploring Wall Street Estimates for Key Metrics
Beyond analysts' top -and-bottom-line estimates for Insulet (PODD), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2024.
08/01 11:06 EST - zacks.com
Insulet (PODD) Earnings Expected to Grow: Should You Buy?
Insulet (PODD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Insulet (PODD) Earnings Expected to Grow: Should You Buy?
Insulet (PODD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
07/30 12:41 EST - zacks.com
EYE vs. PODD: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical - Products sector might want to consider either National Vision (EYE) or Insulet (PODD). But which of these two stocks presents investors with the better value opportunity right now?
EYE vs. PODD: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical - Products sector might want to consider either National Vision (EYE) or Insulet (PODD). But which of these two stocks presents investors with the better value opportunity right now?
07/26 07:08 EST - reuters.com
Insulet expects to beat revenue estimates on strong insulin pump demand
Insulet reported preliminary second-quarter revenue above Wall Street estimates on Friday, as it benefited from strong demand for its insulin delivery devices.
Insulet expects to beat revenue estimates on strong insulin pump demand
Insulet reported preliminary second-quarter revenue above Wall Street estimates on Friday, as it benefited from strong demand for its insulin delivery devices.
07/18 13:02 EST - zacks.com
All You Need to Know About Insulet (PODD) Rating Upgrade to Strong Buy
Insulet (PODD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
All You Need to Know About Insulet (PODD) Rating Upgrade to Strong Buy
Insulet (PODD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
06/25 12:40 EST - zacks.com
ESLOY vs. PODD: Which Stock Is the Better Value Option?
Investors interested in stocks from the Medical - Products sector have probably already heard of EssilorLuxottica Unsponsored ADR (ESLOY) and Insulet (PODD). But which of these two stocks offers value investors a better bang for their buck right now?
ESLOY vs. PODD: Which Stock Is the Better Value Option?
Investors interested in stocks from the Medical - Products sector have probably already heard of EssilorLuxottica Unsponsored ADR (ESLOY) and Insulet (PODD). But which of these two stocks offers value investors a better bang for their buck right now?